MELA Sciences, Inc. Partners With Dermatologists Nationwide To Promote Skin Cancer Awareness

 MELA Sciences, Inc. Partners With Dermatologists Nationwide To Promote Skin
                               Cancer Awareness

FREE MELAFIND® SESSIONS ON MAY 1

PR Newswire

IRVINGTON, N.Y., April 23, 2013

IRVINGTON, N.Y., April 23, 2013 /PRNewswire/ --MELA Sciences, Inc. (NASDAQ:
MELA).

(Logo: http://photos.prnewswire.com/prnh/20130103/NY36051LOGO )

As part of its dedication to help reduce soaring melanoma rates in the United
States, MELA Sciences, Inc. is sponsoring free MelaFind® examinations at
participating dermatologist offices nationwide on May 1, the first day of Skin
Cancer Detection and Prevention Month™.

"Despite advances in sun protection education and sunscreen technology,
melanoma rates continue to rise," said Dr. Joseph Gulfo, President and CEO of
MELA Sciences, Inc. "Experts tells us that the key to saving lives is by
catching skin cancer before it has advanced. We hope this promotion will raise
awareness of the importance of annual skin cancer exams in detecting potential
melanomas."

MelaFind® is the first and only FDA-approved diagnostic tool that helps
dermatologists detect melanoma at its most curable stage. The sophisticated
device uses multi-spectral light technology to quickly, painlessly capture
data about a mole's growth to help dermatologists decide whether the mole
should be biopsied. Consumers can schedule free MelaFind® appointments with
participating dermatologists by visiting www.melafind.com. 

Dr. Gulfo expects that the May 1 promotion will encourage more people to visit
their dermatologist for a thorough skin examination every year, adding the
visit to other annual health exams. According to a Harris survey commissioned
by MELA Sciences Inc., although the majority of Americans have an annual
physical exam (86%), less than one in four Americans (23%) visit a
dermatologist each year for skin exams and professional mole checks.

"I encourage all my patients to conduct skin self-exams regularly and come in
for a professional head to toe evaluation at least once a year, or on your
birthday in your birthday suit," said Dr. Glynis Ablon of the Ablon Institute
in Manhattan Beach, CA, and Associate Professor UCLA.

"We appreciate the support of MELA Sciences, Inc. to motivate patients to take
skin checks more seriously as part of their ongoing commitment to skin cancer
prevention. The advanced technology of MelaFind® allows us to increase our
sensitivity in finding abnormal moles and melanoma. As the risk of pediatric
melanomas is on the rise every year, the ability to detect normal versus
abnormal moles in kids allows us to reduce biopsies which they really
appreciate."

Every hour, one American dies from melanoma, the deadliest form of skin cancer
and the fastest growing cancer in the U.S. Recent studies have shown that
people are being diagnosed with melanoma at a younger age, reinforcing the
need for proper sun protection habits and vigilance about skin cancer
detection.

About MELA Sciences, Inc.
MELA Sciences, Inc. is a medical device company focused on the
commercialization of its flagship product, MelaFind®, and its further design
and development.MelaFind® is a non-invasive tool to provide additional
information to dermatologists during melanoma skin examinations. The device
uses light from visible to near-infrared wavelengths to evaluate skin lesions
up to 2.5 mm beneath the skin. The device provides information on a lesion's
level of morphologic disorganization to provide additional objective
information that may be used by dermatologists in the biopsy decision-making
process. MelaFind® has been approved by the US Food and Drug Administration
for use in the US. In addition, MelaFind® has received CE Mark approval and is
approved for use in the European Union.

For more information on MELA Sciences, Inc., visit www.melasciences.com

Safe Harbor:
This press release includes "forward-looking statements" within the meaning of
the Securities Litigation Reform Act of 1995. These statements include but are
not limited to our plans, objectives, expectations and intentions and other
statements that contain words such as "expects," "contemplates,"
"anticipates," "plans," "intends," "believes," "assumes," "predicts" and
variations of such words or similar expressions that predict or indicate
future events or trends, or that do not relate to historical matters. These
statements are based on our current beliefs or expectations and are inherently
subject to significant known and unknown uncertainties and changes in
circumstances, many of which are beyond our control. There can be no assurance
that our beliefs or expectations will be achieved. Actual results may differ
materially from our beliefs or expectations due to financial, economic,
business, competitive, market, regulatory and political factors or conditions
affecting the company and the medical device industry in general, as well as
more specific risks and uncertainties facing the company such as those set
forth in its reports on Forms 10-Q and 10-K filed with the U.S. Securities and
Exchange Commission (the "SEC"). Factors that might cause such a difference
include whether MelaFind® achieves market acceptance. Given the uncertainties
affecting companies in the medical device industry such as the Company, any or
all of these forward-looking statements may prove to be incorrect. Therefore,
you should not rely on any such factors or forward-looking statements. The
Company urges you to carefully review and consider the disclosures found in
its filings with the SEC which are available at www.sec.gov and
www.melasciences.com.

SOURCE MELA Sciences, Inc.

Website: http://www.melasciences.com
Contact: For Investors: Lynn Pieper, Westwicke Partners, 415-202-5678; For
Media: Erica Sperling, Rpr Marketing Communications, 212-317-1462,
Erica.Sperling@rprmc.com
 
Press spacebar to pause and continue. Press esc to stop.